| Literature DB >> 34174965 |
Xue-Mei Wu1, Xin Yang1, Xian-Cheng Fan2, Xi Chen1, Yu-Xin Wang1, Long-Xian Zhang3, Jun-Ke Song1, Guang-Hui Zhao4.
Abstract
BACKGROUND: Cryptosporidium baileyi is an economically important zoonotic pathogen that causes serious respiratory symptoms in chickens for which no effective control measures are currently available. An accumulating body of evidence indicates the potential and usefulness of metabolomics to further our understanding of the interaction between pathogens and hosts, and to search for new diagnostic or pharmacological biomarkers of complex microorganisms. The aim of this study was to identify the impact of C. baileyi infection on the serum metabolism of chickens and to assess several metabolites as potential diagnostic biomarkers for C. baileyi infection.Entities:
Keywords: Chicken; Cryptosporidium baileyi; Metabolomics; Pathway analysis; Serum sample
Year: 2021 PMID: 34174965 PMCID: PMC8235856 DOI: 10.1186/s13071-021-04834-y
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Fig. 1Score plots of multivariate statistical analysis. a Principal component analysis (PCA) score plots for all samples. Case 1 Cryptosporidium baileyi-infected chickens, Con 1 phosphate buffer saline-inoculated chickens, QC quality control. b Partial least squares-discriminant analysis (PLS-DA) score plots for Case 1 and Con 1 samples, c orthogonal partial least squares-discriminant analysis (OPLS-DA) score plots for Case 1 and Con 1 samples, d results of 200-times response permutation testing of OPLS-DA. Q2 and R2 represent the intercepts of the regression curve and y-axis generated by the linear regression between the R2 and Q2 values of "permuted” model and the R2Y and Q2Y values of the "real" OPLS-DA model, respectively
Each parameter of the multivariate statistical analysis
| Samples | Models | R2X (cumulative) | R2Y (cumulative) | Q2(cumulative) | Q2 |
|---|---|---|---|---|---|
| All | PCA-X | 0.34 | 0.036 | ||
| Case 1–Con 1a | PLS-DA | 0.37 | 0.95 | 0.81 | |
| OPLS-DA | 0.37 | 0.95 | 0.86 | − 0.61 |
R2Y metric describing the percentage of Y matric explained by the model, Q2 (cumulative) metric describing the predictive ability of the model, Q2 metric representing a parameter that describes whether the OPLS-DA opls-da model is over-fitted, PCA principal component analysis, PLS-DA partial least squares-discriminant analysis, OPLS-DA orthogonal partial least squares-discriminant analysis,
aCase 1: experimental group (Cryptosporidium baileyi-infected chickens); Con 1: mock-inoculated (with phosphate buffered saline) group
Fig. 2Expression levels of metabolites between the experimental (Case 1, E1–E9) and mock (Con 1, N1–N9) samples. a Volcano plot for all differential metabolites. Each dot represents one metabolite with detectable expression in both conditions, with the colored dots marking the threshold [false discovery rate (FDR) < 0.05] for defining a metabolite as differentially expressed. Red and blue points represent the significantly upregulated and significantly downregulated metabolites, respectively; gray points indicate non-significant differential metabolites. b Hierarchical cluster analysis of all differential metabolites (FDR < 0.05). Each sample is visualized in a single column and each metabolite is represented by a single row. Red coloration indicates significantly increased metabolite levels, while green coloration indicates low expression (see color scale on figure)
Top 20 serum metabolites following C. baileyi infection in chickens
| Super class | Class | Metabolites | Ion mode | VIP score | FDR ( | log2(FC) | |
|---|---|---|---|---|---|---|---|
| Lipids and lipid-like molecules | Glycerophospholipids | PS(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)) | 758.4397 | Positive | 7.1635 | 0.03205 | 0.6911 |
| PI(O-16:0/12:0) | 758.5170 | Positive | 19.2165 | 0.002712 | 0.7590 | ||
| PI(18:1(11Z)/18:3(6Z,9Z,12Z)) | 857.5210 | Negative | 15.6296 | 4.986E−05 | 2.3144 | ||
| PI(16:2(9Z,12Z)/18:0) | 833.5219 | Negative | 8.0607 | 4.986E−05 | 2.1052 | ||
| PI(16:0/20:4(5Z,8Z,11Z,14Z)) | 857.5225 | Negative | 7.2948 | 0.0005773 | 1.9798 | ||
| PI(16:0/18:2(9Z,12Z)) | 833.5214 | Negative | 12.2832 | 1.376E−05 | 1.6260 | ||
| PE-NMe2(16:0/18:2(9Z,12Z)) | 742.5401 | Negative | 7.3283 | 0.008647 | 0.3866 | ||
| PE(18:1(11Z)/16:0) | 762.5106 | Negative | 8.4451 | 0.01716 | 0.3871 | ||
| PC(18:0/20:4(5Z,8Z,10E,14Z)(12OH[S])) | 808.5876 | Positive | 11.4803 | 0.004282 | 0.3151 | ||
| PC(18:0/18:2(9Z,12Z)) | 830.5920 | Negative | 12.2456 | 0.005834 | 0.6030 | ||
| 1-(8-[5]-ladderane-octanyl)-2-(8-[3] -ladderane-octanyl)-sn-glycerophosphoethanolamine | 740.5361 | Positive | 6.8453 | 0.007720 | 0.4890 | ||
| Sphingolipids | Sphingosine 1-phosphate (d19:1-P) | 808.5930 | Positive | 9.3068 | 0.0006339 | 0.4496 | |
| Sterol lipids | 3alpha,12alpha,15alpha-Trihydroxy-5beta-cholan-24-oic Acid | 834.6075 | Positive | 8.1554 | 0.03314 | 0.3403 | |
| Fatty acyls | Linoleamide | 280.2623 | Positive | 11.4190 | 0.03024 | 0.2028 | |
| Oleamide | 563.5523 | Positive | 6.9537 | 0.004440 | 0.2195 | ||
| 8E-Heneicosene | 312.3620 | Positive | 7.4827 | 0.003657 | 0.2100 | ||
| Unclassified | Unclassified | PC(14:0/22:1(13Z)) | 788.6176 | Positive | 19.1918 | 0.02364 | 1.3638 |
| GlcCer(t18:1(8Z)/18:0(2OH[S])) | 782.5746 | Positive | 13.5588 | 0.01607 | 0.3220 | ||
| GlcCer(t18:1(8Z)/22:0(2OH[S])) | 838.6411 | Positive | 11.4627 | 0.03009 | 0.4810 | ||
| Farnesyl acetone | 263.2360 | Positive | 7.6243 | 0.009272 | 0.2245 |
m/z mass-to-charge ratio, VIP variable importance in projection, FDR false discovery rate, log(FC) log2 fold change
Fig. 3KEGG pathway enrichment analysis of differential serum metabolites following C. baileyi infection. a Significantly enrichments pathways with FDR (q-value) < 0.05. b Relationships between metabolic pathways and differential serum metabolites enriched. Each oval denotes one metabolic pathway. Triangles denote differentially abundant metabolites, with red representing upregulated metabolites
Potential serum biomarkers response to C. baileyi infection in chickens based on receiver operating characteristic curve analysis
| Metabolites | KEGG ID | Ion mode | AUC | VIP | FDR ( | log2(FC) | Pathways (FDR < 0.05) |
|---|---|---|---|---|---|---|---|
| All-trans-retinoic acid | C00777 | Positive | 1.000 | 1.542 | 0.002763 | 0.2638 | Intestinal immune network for IgA production |
| PE(16:1(9Z)/24:1(15Z)) | C00350 | Positive | 0.9012 | 1.184 | 0.01051 | 0.8962 | Glycerophospholipid metabolism, Autophagy–other, Autophagy–animal |
| Sphinganine | C00836 | Positive | 0.9383 | 5.258 | 0.01546 | 0.2760 | Sphingolipid metabolism |
| PC(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | C00157 | Positive | 0.8642 | 1.155 | 0.02174 | 0.4605 | Glycerophospholipid metabolism |
| Phosphocholine | C00588 | Positive | 0.9012 | 1.660 | 0.02200 | 0.3740 | Glycerophospholipid metabolism |
| PC(14:0/22:1(13Z)) | C00157 | Positive | 0.9383 | 19.19 | 0.02364 | 1.364 | Glycerophospholipid metabolism |
| SM(d18:0/16:1(9Z)(OH)) | C00550 | Positive | 0.9259 | 5.159 | 0.02786 | 0.3067 | Sphingolipid metabolism |
| Choline | C00114 | Positive | 0.8765 | 1.257 | 0.04110 | 0.4412 | Glycerophospholipid metabolism |
| Sirolimus | C07909 | Negative | 0.8765 | 2.448 | 0.04846 | 0.1805 | Cellular senescence |
KEGG Kyoto Encyclopedia of Genes and Genomes, AUC area under the curve
Fig. 4Identification of potential biomarkers response to C. baileyi infection. a Potential biomarker metabolites detected in ESI+ mode based on receiver operating characteristic curve analysis, b potential biomarker metabolites detected in ESI− mode based on ROC analysis. ESI Electrospray ionization